Dr Elena De Vita

Elena De Vita

Lecturer in Synthetic Biology and Biotechnology

School of Biological and Behavioural Sciences, Department of Bio
Queen Mary University
020 7882 3063
edv-lab.com
ORCID Google Scholar

Research

Drug discovery, Covalent inhibitors, Induced proximity, PHOSTACs, Protein phopshatases

Cancer Models

Interests

My research involves the development of novel chemical compounds that can help understanding and treating cancer and other debilitating diseases. The use of advanced in vitro models is therefore essential to bring these compounds forward into the drug discovery pipeline.

Publications

Publications of specific relevance to Predictive in vitro Models

2024

Shah RR, De Vita E, Sathyamurthi PS, Conole D, Zhang X, Fellows E, Dickinson ER, Fleites CM, Queisser MA, Harling JD and Tate EW (2024). Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 67, (6) 4641-4654.  

2022

Zhang L, Lovell S, De Vita E, Jagtap PKA, Lucy D, Grocin AG, Kjær S, Borg A, Hennig J, Miller AK and Tate EW (2022). A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell Invasion. American Chemical Society (Acs)  Journal of The American Chemical Society  vol. 144, (49) 22493-22504.  
Jamshidiha M, Lanyon-Hogg T, Sutherell CL, Craven GB, Tersa M, De Vita E, Brustur D, Pérez-Dorado I, Hassan S, Petracca R, Morgan RM, Sanz-Hernández M, Norman JC, Armstrong A, Mann DJ, Cota E and Tate EW (2022). Identification of the first structurally validated covalent ligands of the small GTPase RAB27A. Royal Society of Chemistry (Rsc)  Rsc Medicinal Chemistry  vol. 13, (2) 150-155.  
Zhang Q, Kounde CS, Mondal M, Greenfield JL, Baker JR, Kotelnikov S, Ignatov M, Tinworth CP, Zhang L, Conole D, De Vita E, Kozakov D, McCluskey A, Harling JD, Fuchter MJ and Tate EW (2022). Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs). Royal Society of Chemistry (Rsc)  Chemical Communications  vol. 58, (78) 10933-10936.  

2021

Yoon H, Triplet EM, Simon WL, Choi C, Kleppe LS, De Vita E, Miller AK and Scarisbrick IA (2021). Blocking Kallikrein 6 promotes developmental myelination. Wiley  Glia  vol. 70, (3) 430-450.  
De Vita E, Lucy D and Tate EW (2021). Beyond targeted protein degradation: LD·ATTECs clear cellular lipid droplets. Springer Nature  Cell Research  vol. 31, (9) 945-946.  
Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, Maneiro M, Tanaka RJ, Bevan CL, Clements JA and Tate EW (2021). A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. American Chemical Society (Acs)  Journal of The American Chemical Society  vol. 143, (23) 8911-8924.  
Santamaria S, Buemi F, Nuti E, Cuffaro D, De Vita E, Tuccinardi T, Rossello A, Howell S, Mehmood S, Snijders AP and de Groot R (2021). Development of a fluorogenic ADAMTS-7 substrate. Taylor & Francis  Journal of Enzyme Inhibition and Medicinal Chemistry  vol. 36, (1) 2160-2169.  
Maneiro M, De Vita E, Conole D, Kounde CS, Zhang Q and Tate EW (2021). PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. Elsevier   

2020

De Vita E (2020). 10 years into the resurgence of covalent drugs. Taylor & Francis  Future Medicinal Chemistry  vol. 13, (2) 193-210.  
De Vita E, Maneiro M and Tate EW (2020). The Missing Link between (Un)druggable and Degradable KRAS. American Chemical Society (Acs)  Acs Central Science  vol. 6, (8) 1281-1284.  

2019

De Vita E, Smits N, van den Hurk H, Beck EM, Hewitt J, Baillie G, Russell E, Pannifer A, Hamon V, Morrison A, McElroy SP, Jones P, Ignatenko NA, Gunkel N and Miller AK (2019). Synthesis and Structure‐Activity Relationships of N‐(4‐Benzamidino)‐Oxazolidinones: Potent and Selective Inhibitors of Kallikrein‐Related Peptidase 6. Wiley  Chemmedchem  vol. 15, (1) 79-95.  
D'Andrea F, Nuti E, Becherini S, Cuffaro D, Husanu E, Camodeca C, De Vita E, Zocchi MR, Poggi A, D'Arrigo C, Cappello V, Gemmi M, Nencetti S, Chiappe C and Rossello A (2019). Design and Synthesis of Ionic Liquid‐Based Matrix Metalloproteinase Inhibitors (MMPIs): A Simple Approach to Increase Hydrophilicity and to Develop MMPI‐Coated Gold Nanoparticles. Wiley  Chemmedchem  vol. 14, (6) 686-698.  

2018

De Vita E, Schüler P, Lovell S, Lohbeck J, Kullmann S, Rabinovich E, Sananes A, Heßling B, Hamon V, Papo N, Hess J, Tate EW, Gunkel N and Miller AK (2018). Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity. American Chemical Society (Acs)  Journal of Medicinal Chemistry  vol. 61, (19) 8859-8874.  
Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, Radisky ES and Papo N (2018). A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. Elsevier  Journal of Biological Chemistry  vol. 293, (33) 12663-12680.  
Longuespée R, Wefers AK, De Vita E, Miller AK, Reuss DE, Wick W, Herold-Mende C, Kriegsmann M, Schirmacher P, von Deimling A and Pusch S (2018). Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Springer Nature  Acta Neuropathologica Communications  vol. 6, (1)